Article Sidebar

Download
PDF
Statistic
Read Counter : 148 Download : 177

Main Article Content

Abstract

Coronary heart disease (CHD) is a generic designation for a group of related syndromes resulting from myocardial ischemia – an imbalance between cardiac blood supply (perfusion) and myocardial oxygen demand. Visfatin (VF)  is a recently discovered adipokine with different functions, Visfatin is mainly found in visceral adipose tissue and mimics insulin in lowering plasma glucose levels and, Visfatin emerges as a player in the development and progression of atherosclerotic lesions by directly promoting smooth muscle cell proliferation, Aberrant angiogenesis is now considered a feature of the atherogenic process in both coronary and carotid diseases. This adipokine was previously known as a pre-B-cell colony-enhancing factor   (PBEF) or  Nicotinamide phosphoribosyltransferase (NAmPRTase or Nampt) an enzyme that in humans is encoded by the NAMPT gene  and demonstrated to be an intracellular protein with a key enzyme role in nicotinamide adenine dinucleotide (NAD)

Keywords

Coronary heart diseases Visfatin adipokine pre-B-cell colony-enhancing factor (PBEF)

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Al-Kraity, A. P. D. W. R. H., Faisal, A. H., Khaleel, A. N., Naeaam, M. T., & Jabar, A. S. (2021). Description of Visfatin Adipokine and its Roles on Inflammation and Coronary Heart Disease: A Review Study. Medical Science Journal for Advance Research, 2(1), 10–14. https://doi.org/10.46966/msjar.v2i1.13
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Bae, Y.; Bae, M.; Kim, S.; Lee, J.; Wee, H. and Bae, S. (2009). Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochemical and Biophysical Research Communications, 379.(2): 206–211.
  2. Costford, S.R.; Bajpeyi, S.; Pasarica, M.; Albarado, D.C.; Thomas, S.C.; Xie, H. and et al.(2010). Skeletal muscle NAMPT is induced
  3. by exercise in humans. American Journal of Physiology –Endocrinology and Metabolism, 298(1): 117–26.
  4. Curat , C.A.; Wegner, V.; Sengenes, C,.; Miranville, A.; Tonus, C.; Busse, R. and et al. (2006). Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia, 49(4): 744-747.
  5. Dahl, T.; Yndestad, A.; Skjelland, M. and et al.(2007). Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation, 115(8) : 972–980.
  6. De-Clercq, V.; Taylor, C. and Zahradka, P.(2008). Adipose tissue: the link between obesity and cardiovascular disease. Cardiovasc. Hematol. Disord. Drug Targets,8:228-37.
  7. Dragovich, P.; Zhao, G.; Baumeister T.; Bravo, B. and Giannetti, A.(2014). Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Bioorganic & Medicinal Chemistry Letters, 24, (3): 954-962.
  8. Filippatos, T.D.; Randeva, H.S.; Derdemezis, C.S.; Elisaf, M.S. and Mikhailidis, D.P. (2010). Visfatin/PBEF and atherosclerosis-related diseases. Curr. Vasc. Pharmacol., 8:12-28.
  9. • Filippatos, T.D.; Tsimihodimos, V.; Derdemezis, C.S.; Gazi, I.F.;Saougos, V.; Mikhailidis, D.P. and et al. (2013). Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr. Metab. Cardiovasc. Dis., 23:330-6.
  10. Flier, J.s.; Flier, E.m., Wiener, C.; Fauci A.S. and et al. (2007). Biology of Obesity. In: Harrison’s Principles of Internal Medicine . The Mcgraw-Hill Companies Inc, New York, pp. 462- 472.
  11. Fukuhara, A.; Matsuda, M.; Nishizawa, M.; Segawa, K.; Tanaka, M. and et al. (2005). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307: 426-430.
  12. Garten, A.; Petzold, S.; Barnikol-Oettler, A.; Korner, A.; Thasler, W.E.; Kratzsch, J. and et al. (2010). Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochemical and Biophysical Research Communications, 2010;391(January (1)):376–81.
  13. Gürsoy, M.; Duygu, E.; Hökenek, A.F.; Gülcan, F. and Kınoğlu, B. (2014). Serum Visfatin Levels and Coronary Artery Disease. Koşuyolu Heart Journal, 17(2):95-99.
  14. Jia, S.H.; Li, Y.; Parodo, J.; Kapus, A.; Fan, L.; Rotstein, O.D. and et al.(2004). Pre-B cell colony enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. Journal of Clinical Investigation, 113(9):1318–27.
  15. Kim, M.k.; Lee, J.h.; Kim, H.; Park, S.j.; Kim, S.h.; Kang, G.b. et al., (2006). Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. Mol. Biol., 362: 66-77.
  16. Kitani, T.; Okuno, S. and Fujisawa, H. (2003). Growth phasedependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS. Lett., 544:74-8.
  17. Lee, W.; Wu, C.; Lin, H. and et al. (2009). Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. International Journal of Obesity, 33 (4):465–472.
  18. Li, Y.; Zhang, Y.; Dorweiler, B. and et al.(2008). Extracellularnampt promotes macrophage survival via a nonenzymatic interleukin- 6/STAT3 signaling mechanism. Journal of Biological Chemistry, 283(50):34833–34843.
  19. Matsuda, F. and Nishizawa, M. et al. (2005). Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin. Sci., 2005; 307:426–30.
  20. Mazaherioun, M.; Hosseinzadeh-Attar, M.J.; Janani, L.; Vasheghani Farahani, A.; Rezvan, N.; Karbaschian, Z. and et al. (2012). Elevated serum visfatin levels in patients with acute myocardial infarction. Arch. Iran Med., 15(11): 688 – 692.
  21. Moschen, A. .; Kaser, A.; Enrich, B. and et al. (2007). “Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology, 178(3): 1748– 1758.
  22. Moschen,. AR.; Gerner, R.R. and Tilg, H. (2010). Pre-B cell colony enhancing factor in inflammation and obesity –related disorders. Curr. Pharm. Des., 16(17):1913-20.
  23. Moulton, K.S.(2006). Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Current Opinion in Lipidology, 17(5):548–555.
  24. Naveen, G. (2009). A study of lipid profile in smokers and it is association in ischemic heart disease, Dissertation, M.D (General Medicine), P39.
  25. Olszanecka, G.; Linianowicz, M.; Kocelak, P.; Janowska, J.; Skorupa, A.; Nylec, M. and Zahorska , M. (2011). Plasma visfatin and tumor necrosis factor –alpha level in metabolic syndrome. Kardiol. Pol., 69(8):802-7.
  26. Omer, R. and Mahmood, M. (2016). Correlation between Visfatin and Creatine Kinase Levels with Periodontal Health Status of Patients with Coronary Atherosclerosis and Chronic Periodontitis. (J. Bagh. Coll. Dentistry, 28(3):121-125)
  27. Raman, T. (2013). Adipokines, structure of visfatin. Health & Medicine, Technology J.
  28. Romacho, T.; Azcutia, V.; Vazquez-Bella, M.; Matesanz, N.; Cercas, E. and et al. (2009). Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth
  29. muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 52 (11)2455–2463.
  30. Romacho, T.; Sánchez-Ferrer, C. and Peiró, C. (2013).
  31. Visfatin/Nampt: An Adipokine with Cardiovascular Impact. Mediators of Inflammation, 15 pages.
  32. Rydén, L.; Standl. E.; Bartnik, M.; Van den Berghe, G.; Betteridge J.; de Boer. M.J.; Cosentino, F. and Jönsson, B. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur. Heart J., 28, 88-136.
  33. Samal, B.; Sun, Y.; Stearns, G.; Xie, C.; Suggs, S. and McNiece, I. (1994). Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molecular and Cellular Biology, 14 (2):1431–7.
  34. Sebregts, E.H.; Falger, P.R and Bar, F.W. (2000). Risk factor modification through non-pharmacological interventions in patients with coronary heart diseases. Journal of Psychosomatic Research, 48: 425- 41.
  35. Shaker, O.; El-Shehaby, A.; Zakaria, A.; Mostafa, N.; Talaat, S.; Katsiki, N. and et al.(2011). Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. Clin. Biochem., 44:1457-63.
  36. Stofkova, A. (2010). Resisiten and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr. Regul., 44: 25-36.
  37. Trivedi, D. and Chhaya, T. (2012). Salivary proteome in periodontal diagnosis. International. J. Pharma. and Bio.Sci., 2:5-9.
  38. Wang, L.S.; Yan, J.J.; Tang, N.P.; Zhu, J.; Wang, Y.S. and et al., (2011). polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol. Biol, Rep., 38(2): 819-25.
  39. Wang, P.; Xu, T.; Guan, Y.; Su, D.; Fan, G. and C. Miao, C. (2009). Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide, Cardiovascular Research, 81 (2): 370–380.
  40. Wang, T.; Zhang, X.; Bheda, P.; Revollo, J.r.; Imai, S. and Wolberger, C. (2006). Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol. 13:661-662.